Screener
UroGen Pharma URGN Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities related to finance leases | 1,411 | 1,274 |
| Current liabilities related to operating leases | 684 | 481 |
| Other current liabilities | 7,622 | 3,430 |
| Total current liabilities | 61,915 | 46,418 |
| Non-current liabilities: | ||
| Prepaid forward obligation | 125,135 | 127,276 |
| Long-term debt | 188,734 | 122,210 |
| Finance long-term lease liabilities | 2,939 | 3,475 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's total current liabilities?
- UroGen Pharma (URGN) reported total current liabilities of $61.92M in Q2 2026.
- How has UroGen Pharma's total current liabilities changed year-over-year?
- UroGen Pharma's total current liabilities increased by 30.2% year-over-year, from $47.55M to $61.92M.
- What is the long-term trend for UroGen Pharma's total current liabilities?
- Over 5 years (2020 to 2025), UroGen Pharma's total current liabilities has grown at a 16.7% compound annual growth rate (CAGR), from $21.44M to $46.42M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about UroGen Pharma's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude